Related Experiment Videos
[CD 143 expression in benign and malignant vascular tumors]
R M Bohle1, B Klöpper, F E Franke
1Institut für Pathologie, Universität Giessen.
Verhandlungen Der Deutschen Gesellschaft Fur Pathologie
|March 30, 1999
Summary
CD 143 (angiotensin-I-converting enzyme) is expressed in most benign and malignant endothelial tumors, aiding in their identification. Co-expression of CD 143 and CD 31 effectively distinguishes between intermediate and malignant vascular tumors.
Area of Science:
- Oncology
- Pathology
- Immunohistochemistry
Background:
- Somatic CD 143 (angiotensin-I-converting enzyme) is present in human endothelial cells.
- CD 143 overexpression is observed in pathological conditions like myocardial infarctions and atherosclerotic plaques.
- CD 143's role as an endothelial differentiation marker in tumors requires further investigation.
Purpose of the Study:
- To evaluate CD 143 as a marker for endothelial differentiation in vascular and perivascular tumors.
- To assess the utility of CD 143 in conjunction with CD 31 and CD 34 for tumor classification.
- To differentiate between benign and malignant endothelial tumors using immunohistochemical markers.
Main Methods:
- Investigated 39 formalin-fixed, paraffin-embedded benign and malignant tumors.
- Utilized APAAP immunohistochemistry with epitope retrieval techniques.
- Analyzed expression patterns of CD 143, CD 31, and CD 34 qualitatively and semiquantitatively.
Main Results:
- CD 143 was detected in the majority of benign and malignant vascular tumors.
- All haemangiopericytomas (benign and malignant) were CD 143 negative.
- Co-expression of CD 143 and CD 31 identified all haemangioendotheliomas and angiosarcomas.
Conclusions:
- Most benign and malignant endothelial tumors express CD 143.
- CD 143 is a valuable marker for endothelial differentiation in tumors.
- Combined analysis of CD 143 and CD 31 co-expression provides the best discrimination for intermediate and malignant endothelial tumors.